Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05564156 |
| Other study ID # |
Pharm. Role Resp. Disease Ward |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 30, 2020 |
| Est. completion date |
December 31, 2021 |
Study information
| Verified date |
October 2022 |
| Source |
Bezmialem Vakif University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Clinical pharmacists in the healthcare system are experts in therapeutics and the use of
drugs. They routinely provide medication reviews and recommendations to patients and
healthcare professionals. Clinical pharmacists are a scientifically valid source of
information and give advice on the safe and appropriate use of medicines and
pharmacoeconomics. Clinical pharmacist researchers produce, distribute and apply new
information that contributes to improving health and quality of life. Thus, it is ensured
that many of the drug treatment errors that occur after inappropriate therapeutic decisions
are made at the point of prescribing are prevented
In this investigation, the effects of clinical pharmacists on respiratory would be
investigated. This research area will cover lower respiratory tract infections and chronic
lung disease exacerbations with ICD-10 codes J05, J9-22, J40-47, J69, J85 -J86. In this
study, two groups, control and intervention groups, were identified. In the control group;
There will be no intervention done by the Clinical Pharmacist. Hospital stay, antimicrobial
suitability, microbial resistance development, antimicrobial induced nephrotoxicity,
infection-related mortality, pharmacoeconomic evaluation, re-hospitalization within 30 days
after discharged, medication reconciliation report will be created, patients will be
monitored for the detection and management of drug-related problems will be recorded in both
control and intervention groups. In the intervention group; recommendations will be given to
the physicians by the Clinical Pharmacist on the selection of antibiotics, drug suitability,
dosage and route of administration advice, and determination of drug-related problems related
to drugs used simultaneously.
Description:
The literature shows the benefit of including the pharmacist in microbiological test review
and follow-up. The inclusion of a pharmacist in antibiotic management processes can result in
the more reasonable use of antimicrobial agents and more efficient monitoring with patients
and/or caregivers. Healthcare policymakers and administrators who evaluate processes to
increase efficiency and improve care for patients suspected of discharged infections should
examine the effectiveness of clinical pharmacists in the CAP.
Urgent action is needed to tackle the growing resistance threat. Antimicrobial stewardship
programs (AYP) have resulted in slowing down antimicrobial resistance and improving
antimicrobial prescribing practices that can maintain existing antimicrobial treatments. The
CDC and Joint Commission have published recommendations and standards for the conduct of
antimicrobial management in both inpatient and outpatient treatment. Although the main
principles of the program of antimicrobial management have been established for over a
decade, AYPs are constantly evolving, and improving program efficiency brings new approaches
to patient care. Although it is one of the main goals of antimicrobial management, the direct
effects of AYP interventions on reducing antimicrobial resistance are often immeasurable and
multi-factorial. Therefore, interventions aimed at minimizing the use of inappropriate
antibiotics, including unnecessary and insufficient use, are often used to measure the effect
of AYPs on resistance.
Clinical pharmacists in the healthcare system are experts in therapeutics and the use of
drugs. They routinely provide medication reviews and recommendations to patients and
healthcare professionals. Clinical pharmacists are a scientifically valid source of
information and give advice on the safe and appropriate use of medicines and
pharmacoeconomics. Clinical pharmacist researchers produce, distribute and apply new
information that contributes to improving health and quality of life.
Clinical pharmacists care about patients in all healthcare areas. They do not only provide
clinical services, but they also provide care to their patients and they can perform this
application in any application environment. In other words, clinical pharmacists interact and
observe directly with the patient. Also, managing treatment directly in patient care settings
is particularly important as it reinforces the existing definitions of the term "clinical".
In addition, this specialization is used proactively to provide and advance rational drug
therapy. Thus, it is ensured that many of the drug treatment errors that occur after
inappropriate therapeutic decisions are made at the point of prescribing are prevented.
In this study, two groups, control and intervention groups, were identified. In the control
group; There will be no intervention done by the Clinical Pharmacist. Hospital stay,
antimicrobial suitability, microbial resistance development, antimicrobial induced
nephrotoxicity, infection-related mortality, pharmacoeconomic evaluation, re-hospitalization
within 30 days after discharged, medication reconciliation report will be created, patients
will be monitored for the detection and management of drug-related problems will be recorded
in both control and intervention groups. In the intervention group; recommendations will be
given to the physicians by the Clinical Pharmacist on the selection of antibiotics, drug
suitability, dosage and route of administration advice, and determination of drug-related
problems related to drugs used simultaneously.
